Previous 10 | Next 10 |
2023-03-07 12:39:41 ET Gainers: ThredUp ( TDUP ) +73% . WW International ( WW ) +49% . Unicycive ( UNCY ) +39% . Protagonist Therapeutics ( PTGX ) +32% . Bionomics ( BNOX ) +28% . Novo Integrated Sciences ( NVOS ) +25% ...
2023-03-07 11:28:43 ET Gainers: Unicycive ( UNCY ) +52% . Bionomics ( BNOX ) +49% . Novo Integrated Sciences ( NVOS ) +37% . Protagonist Therapeutics ( PTGX ) +34% . Allakos ( ALLK ) +22% . Losers: Cara ( CARA ) -28...
2023-03-07 09:00:19 ET Protagonist Therapeutics ( NASDAQ: PTGX ) added ~16% pre-market Tuesday after announcing that the plaque psoriasis candidate JNJ-2113, it co-develops with the Janssen unit of Johnson & Johnson, reached the main goal in a Phase 2 trial. The FRON...
Protagonist Therapeutics Announces Positive Topline Results for Phase 2b FRONTIER 1 Clinical Trial of Oral IL-23 Receptor Antagonist JNJ-2113 (PN-235) in Psoriasis PR Newswire JNJ-2113 (formerly PN-235) met the study's primary endpoint, with a statistically significantly h...
Protagonist Therapeutics to Participate in the JMP Securities Hematology and Oncology Summit PR Newswire NEWARK, Calif. , Dec. 1, 2022 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. ...
Protagonist press release ( NASDAQ: PTGX ): Q3 GAAP EPS of -$0.64 beats by $0.23 . The company expects current cash, cash equivalents and marketable securities of $267.4M to be sufficient to fund its planned operating and capital expenditures through the end of 2024. ...
Protagonist Reports Third Quarter 2022 Financial Results and Provides Corporate Update PR Newswire Continued execution of Phase 3 VERIFY study of rusfertide in polycythemia vera Arturo Molina , M.D., M.S. named Chief Medical Officer, providing medical, clin...
Protagonist Therapeutics Announces Poster Presentations at the American Society of Hematology 2022 Annual Meeting PR Newswire NEWARK, Calif. , Nov. 3 , 2022 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") anno...
Protagonist Announces Appointment of Arturo Molina, M.D., M.S., F.A.C.P. as Chief Medical Officer PR Newswire Accomplished hematologist-oncologist will provide medical, clinical development, and strategic operational leadership to the ongoing rusfertide Phase 3 develop...
Protagonist Reports Second Quarter 2022 Financial Results and Provides Corporate Update PR Newswire Continued focus on Phase 3 VERIFY study of rusfertide in polycythemia vera (PV) Presented new, positive data from Phase 2 REVIVE study of rusfertide in PV at the...
News, Short Squeeze, Breakout and More Instantly...
Protagonist Therapeutics Inc. Company Name:
PTGX Stock Symbol:
NASDAQ Market:
Protagonist Therapeutics Inc. Website:
NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of preclinical and phase 1 clinical data on JNJ-2113 in the journal Scientific Reports , a Nature publication and the 5th most-cited journal in the world, acc...
NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of preclinical and phase 1 clinical data on JNJ-2113 in the journal Scientific Reports , a Nature publication and the 5th most-cited journal in the world, acc...
Dr. Yeilding joins Protagonist from Janssen Pharmaceutical Companies of Johnson & Johnson, where he held leadership roles in the immunology therapeutic area, bringing extensive experience in R&D and commercialization of novel therapeutics in the I&I space NEWARK, CA / ACCESSWIRE /...